Back to search results

Study of NSHO-101 in Healthy Participants

This study is looking for healthy volunteers to help us understand how a new medication called NSHO-101 works in the body. We want to learn how much of NSHO-101 gets into your system (pharmacokinetics), if it's safe to take, and if you can tolerate it well. You would take NSHO-101 as a tablet once a day for 14 days. We'll measure how much NSHO-101 is in your blood at different times for up to 18 days to see how it's absorbed and cleared. This study is currently recruiting about 24 healthy adults, aged 18 and older, who are in good health and willing to follow study procedures.

Study design
This is an interventional study involving approximately 24 healthy participants. It is not specified if the study is randomized, blinded, or what phase it is.
What's involved
You would take NSHO-101 as a tablet once a day for 14 days. Blood samples would be collected to measure NSHO-101 levels for up to 18 days.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels of NSHO-101 will be measured for up to 18 days after you start taking the medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07403552

Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

Recruiting
PHASE1Ages 18+Interventional
Ensho Therapeutics, Inc.
~24 participants
Updated 2026-02-11 on ClinicalTrials.gov
What's tested:NSHO-101

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pharmacokinetics: Maximum Concentration (Cmax)
Measured over Day 1 to Day 18
+4 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
California1

Who to contact

Bittoo Kanwar, MD, MD
[email protected]
973-314-8995
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants (males and females) at least 18 years of age
Ability to provide written informed consent
In good heath as determined by medical evaluation,
Willing and able to comply with trial restrictions, procedures, and requirements

Exclusion

Known sensitivity to any components of the IMP
History of relevant drug hypersensitivity
Presents or has a history of clinically significant diseases
History of difficulty swallowing tablets or capsules.
Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.

What this trial measures

  • Pharmacokinetics: Maximum Concentration (Cmax)Day 1 to Day 18
  • Pharmacokinetics: Area Under the Concentration Curve (AUC)Day 1 to Day 18
  • Pharmacokinetics: Trough Concentration (Ctrough)Day 1 to Day 18
  • Pharmacokinetics: Half-lifeDay 1 to Day 18
  • Pharmacokinetics: Time to Maximum Concentration (tmax)Day 1 to Day 18